Epiphany Biosciences, Inc.: Series A $36M

Epiphany Biosciences (San Francisco, CA) is developing both therapeutic products and diagnostic technologies that treat or prevent the spread of pathogenic viruses a new with its lead product for the treatment of Shingles closed a $36M Series A. The round was led by Wexford Capital other participants included Windsor Bay Capital, Global Trust Ventures Management and CDIB BioScience Venture Management.